FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480270932> ?p ?o ?g. }

• W2480270932 abstract "PP2A is a phosphatase tumor suppressor that is dysregulated and deactivated in lung cancer. It is one of the most abundant cellular proteins and regulates the activity of numerous kinases Where achievable, restoration of PP2A function inhibits cancer progression, and notably, by the inhibition of the downstream effectors of the oncogenic kinases that initiate and drive cancer progression. In this study, we determined PP2A inactivation in human lung cancer with specific molecular genotypes and we ascertained the biological and functional consequences of PP2A reactivation. In assessing a lung cancer TMA, we identified that PP2A inactivation was correlated with poor survival and was significantly higher in patients with Kras mutations. In order to understand the therapeutic potential of restoration of PP2A activity in KRAS mutant lung cancer, our lab developed a series of small molecule activators of PP2A (SMAPs) through reverse engineering of tricyclic neuroleptic drugs. SMAP treatment of lung cancer cell lines resulted in an induction of apoptosis and decreased cell viability. Structural and biophysical studies have identified the site of drug binding and mechanism for PP2A activation by this small molecule series. Additionally, cell lines harboring drug-binding mutations were resistant to SMAP therapy as compared to wild type PP2A and EGFP control. Global phosphoproteomic analysis of SMAP treated KRAS lung cancer cell lines revealed ERK signaling as a commonly perturbed pathway in drug treated cell lines. Given the marked dephosphorylation of ERK upon treatment of cell lines with SMAPs, we overexpressed a constitutively active form of MEK (MEKDD) to blunt SMAP mediated ERK dephosphorylation to determine the relevance of ERK inactivation for the biological effects of SMAPs on cellular apoptosis. Overexpression of MEKDD resulted in a blunted apoptotic response to SMAP treatment. Single agent SMAP treatment of KRAS GEMM and xenograft mouse models of lung cancer resulted in tumor stasis, induction of tumor cell apoptosis and cell cycle arrest to comparable levels seen with a combination of AKT and MEK inhibitors. Western blotting and immunohistochemical analysis of the tumors demonstrated that SMAP treatment resulted in of ERK, AKT, and PP2A-Y307 dephosphorylation in vivo. Additionally, these compounds demonstrate favorable pharmacokinetics and show no overt toxicity. Furthermore, combination of SMAPs with kinase inhibitors further decreased tumor growth in vivo. Taken together, these findings point to therapeutic activation of PP2A as a novel strategy for the treatment of KRAS-mutant NSCLC. Citation Format: Jaya Sangodkar, Rita Tohme, Janna Kiselar, Sudeh Izadmehr, Divya Hoon, Sahar Mazhar, Abbey Perl, Danica Wiredja, Daniela Schlatzer, Shen Yao, David Kastrinsky, Neelesh Sharma, David Brautigan, Mark Chance, Alain Borczuk, Michael Ohlmeyer, Yiannis Ioannou, Goutham Narla. Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3865." @default.
• W2480270932 created "2016-08-23" @default.
• W2480270932 creator A5002110784 @default.
• W2480270932 creator A5011148019 @default.
• W2480270932 creator A5011707402 @default.
• W2480270932 creator A5014280061 @default.
• W2480270932 creator A5016466462 @default.
• W2480270932 creator A5035205865 @default.
• W2480270932 creator A5036383068 @default.
• W2480270932 creator A5038773259 @default.
• W2480270932 creator A5041677297 @default.
• W2480270932 creator A5042282253 @default.
• W2480270932 creator A5048856568 @default.
• W2480270932 creator A5060000277 @default.
• W2480270932 creator A5061826734 @default.
• W2480270932 creator A5066125347 @default.
• W2480270932 creator A5070544062 @default.
• W2480270932 creator A5071940002 @default.
• W2480270932 creator A5074981380 @default.
• W2480270932 creator A5085939998 @default.
• W2480270932 date "2016-07-15" @default.
• W2480270932 modified "2023-09-25" @default.
• W2480270932 title "Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer" @default.
• W2480270932 doi "https://doi.org/10.1158/1538-7445.am2016-3865" @default.
• W2480270932 hasPublicationYear "2016" @default.
• W2480270932 type Work @default.
• W2480270932 sameAs 2480270932 @default.
• W2480270932 citedByCount "0" @default.
• W2480270932 crossrefType "proceedings-article" @default.
• W2480270932 hasAuthorship W2480270932A5002110784 @default.
• W2480270932 hasAuthorship W2480270932A5011148019 @default.
• W2480270932 hasAuthorship W2480270932A5011707402 @default.
• W2480270932 hasAuthorship W2480270932A5014280061 @default.
• W2480270932 hasAuthorship W2480270932A5016466462 @default.
• W2480270932 hasAuthorship W2480270932A5035205865 @default.
• W2480270932 hasAuthorship W2480270932A5036383068 @default.
• W2480270932 hasAuthorship W2480270932A5038773259 @default.
• W2480270932 hasAuthorship W2480270932A5041677297 @default.
• W2480270932 hasAuthorship W2480270932A5042282253 @default.
• W2480270932 hasAuthorship W2480270932A5048856568 @default.
• W2480270932 hasAuthorship W2480270932A5060000277 @default.
• W2480270932 hasAuthorship W2480270932A5061826734 @default.
• W2480270932 hasAuthorship W2480270932A5066125347 @default.
• W2480270932 hasAuthorship W2480270932A5070544062 @default.
• W2480270932 hasAuthorship W2480270932A5071940002 @default.
• W2480270932 hasAuthorship W2480270932A5074981380 @default.
• W2480270932 hasAuthorship W2480270932A5085939998 @default.
• W2480270932 hasConcept C11960822 @default.
• W2480270932 hasConcept C121608353 @default.
• W2480270932 hasConcept C126322002 @default.
• W2480270932 hasConcept C178666793 @default.
• W2480270932 hasConcept C181912034 @default.
• W2480270932 hasConcept C184235292 @default.
• W2480270932 hasConcept C2776256026 @default.
• W2480270932 hasConcept C2781187634 @default.
• W2480270932 hasConcept C389152 @default.
• W2480270932 hasConcept C502942594 @default.
• W2480270932 hasConcept C526805850 @default.
• W2480270932 hasConcept C54355233 @default.
• W2480270932 hasConcept C57074206 @default.
• W2480270932 hasConcept C71924100 @default.
• W2480270932 hasConcept C86803240 @default.
• W2480270932 hasConcept C95444343 @default.
• W2480270932 hasConcept C96232424 @default.
• W2480270932 hasConceptScore W2480270932C11960822 @default.
• W2480270932 hasConceptScore W2480270932C121608353 @default.
• W2480270932 hasConceptScore W2480270932C126322002 @default.
• W2480270932 hasConceptScore W2480270932C178666793 @default.
• W2480270932 hasConceptScore W2480270932C181912034 @default.
• W2480270932 hasConceptScore W2480270932C184235292 @default.
• W2480270932 hasConceptScore W2480270932C2776256026 @default.
• W2480270932 hasConceptScore W2480270932C2781187634 @default.
• W2480270932 hasConceptScore W2480270932C389152 @default.
• W2480270932 hasConceptScore W2480270932C502942594 @default.
• W2480270932 hasConceptScore W2480270932C526805850 @default.
• W2480270932 hasConceptScore W2480270932C54355233 @default.
• W2480270932 hasConceptScore W2480270932C57074206 @default.
• W2480270932 hasConceptScore W2480270932C71924100 @default.
• W2480270932 hasConceptScore W2480270932C86803240 @default.
• W2480270932 hasConceptScore W2480270932C95444343 @default.
• W2480270932 hasConceptScore W2480270932C96232424 @default.
• W2480270932 hasLocation W24802709321 @default.
• W2480270932 hasOpenAccess W2480270932 @default.
• W2480270932 hasPrimaryLocation W24802709321 @default.
• W2480270932 hasRelatedWork W2013651297 @default.
• W2480270932 hasRelatedWork W2033113987 @default.
• W2480270932 hasRelatedWork W2050307609 @default.
• W2480270932 hasRelatedWork W2051264860 @default.
• W2480270932 hasRelatedWork W2051582766 @default.
• W2480270932 hasRelatedWork W2056667604 @default.
• W2480270932 hasRelatedWork W2057940570 @default.
• W2480270932 hasRelatedWork W2312435024 @default.
• W2480270932 hasRelatedWork W2315292177 @default.
• W2480270932 hasRelatedWork W2559679969 @default.
• W2480270932 hasRelatedWork W2562978274 @default.
• W2480270932 hasRelatedWork W2563962027 @default.
• W2480270932 hasRelatedWork W2738617126 @default.
• W2480270932 hasRelatedWork W2740366217 @default.
• W2480270932 hasRelatedWork W2785719984 @default.
• W2480270932 hasRelatedWork W2810890977 @default.

• next